Literature DB >> 11598856

Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.

R D Craver1, J T Lipscomb, D Suskind, M C Velez.   

Abstract

A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension. A predominant neuroepithelial pattern had ependymal rosettes and mitoses, stained for neuron-specific enolase, neuron-specific B tubulin, and synaptophysin. A malignant spindle cell component stained for smooth-muscle actin, muscle actin, and to a lesser extent S-100. Loose myxoid tissue resembled primitive cartilage. Epithelial membrane antigen and cytokeratin identified epithelial foci. Chromogranin A, MIC2, glial fibrillary acidic protein, and thyroid stimulating hormone receptor stains were negative. There was focal anaplasia. DNA ploidy by laser scanning cytometry was 1.2. The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines. She was treated with aggressive combination chemotherapy and radiation. Presently there is no residual disease 16 months after diagnosis. Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis. Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease. The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor. Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma. Therapy should be tailored to the management of all transformed histologies. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11598856     DOI: 10.1053/adpa.2001.27918

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  6 in total

1.  Primary malignant teratoma with a primitive neuroectodermal tumor component in thyroid gland: a case report.

Authors:  Eunyoung Kim; Tae Seok Bae; Youngmee Kwon; Tae Hyun Kim; Ki-Wook Chung; Sun Wook Kim; Jungsil Ro; Eun Sook Lee
Journal:  J Korean Med Sci       Date:  2007-06       Impact factor: 2.153

2.  Primary thyroid teratoma in adults: A case report and systematic review of the literature.

Authors:  Constantinos Nastos; Anna Paspala; Mathew Stamelos; Ioanna Mavroeidi; Konstantinos Proikas; Georgia Thomopoulou; Amanda Psyrri; Emmanuil Pikoulis
Journal:  Mol Clin Oncol       Date:  2021-06-23

3.  Primitive neuroectodermal tumor originating from the lung: A case report.

Authors:  Xin Jin; Jianfeng Cao; Yong Liu; Fang Bian; Qingqing Zhao; Yan Wang; Xu Lv; Yayong Huang
Journal:  Oncol Lett       Date:  2016-08-08       Impact factor: 2.967

4.  Malignant thyroid teratoma: report of an aggressive tumor in a 64-year-old man.

Authors:  R Vilallonga; C Zafon; C Ruiz-Marcellan; G Obiols; J M Fort; J A Baena; B Villanueva; A Garcia; M Sobrinho-Simões
Journal:  Endocr Pathol       Date:  2013-09       Impact factor: 3.943

5.  Conservative multimodal management of a primitive neuroectodermal tumor of the thyroid.

Authors:  Romain Natale; Juliette Thariat; Pierre Olivier Vedrine; Alex Bozec; Isabelle Peyrottes; Pierre Yves Marcy; Juliette Haudebourg; Florence Pedeutour; Esma Saâda; Antoine Thyss
Journal:  Rare Tumors       Date:  2013-05-29

6.  Malignant teratoid tumor of the thyroid gland: an aggressive primitive multiphenotypic malignancy showing organotypical elements and frequent DICER1 alterations-is the term "thyroblastoma" more appropriate?

Authors:  Abbas Agaimy; Leora Witkowski; Robert Stoehr; Joseph Christopher Castillo Cuenca; Carlos Alberto González-Muller; Alfred Brütting; Markus Bährle; Konstantinos Mantsopoulos; Randa M S Amin; Arndt Hartmann; Markus Metzler; Samir S Amr; William D Foulkes; Manuel Sobrinho-Simões; Catarina Eloy
Journal:  Virchows Arch       Date:  2020-06-07       Impact factor: 4.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.